Carlos Manuel de Castro III

Carlos Manuel de Castro III
Professor of Medicine

Clinical research projects have focused on new and innovative treatments for myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, adult leukemias, and lymphomas

Current Appointments & Affiliations

Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2021
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1988

Contact Information

Box 3961 Med Ctr, Durham, NC 27710
Box 3961, 2400 Pratt St North Pavilion Suite 5000, Durham, NC 27710
decas003@mc.duke.edu (919) 684-8964

Background
Education, Training, & Certifications
- Fellow in Hematology-Oncology, Medicine, Duke University 1988 - 1991
- Resident, Medicine, University of Texas at Dallas 1985 - 1988
- M.D., University of Texas at Dallas 1985
Previous Appointments & Affiliations
- Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2017 - 2020
- Professor of Medicine, Medicine, Hematological Malignancies, Medicine 2012 - 2017
- Professor of Medicine, Medicine, Medical Oncology, Medicine 2010 - 2012
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2006 - 2010
- Associate Clinical Professor of Medicine, Medicine, Medical Oncology, Medicine 2004 - 2006
- Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 1994 - 2004
- Associate in the Department of Medicine, Medicine, Medical Oncology, Medicine 1991 - 1994
Research
Selected Grants
External Relationships
- Alexion Pharmaceuticals, Inc.
- Apellis Pharmaceuticals
- BioCryst Pharmaceuticals
- Novartis
- Regeneron Pharmaceuticals
- Taiho
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Pabon, Cindy M., Zhiguo Li, Therese Hennig, Carlos de Castro, Jadee L. Neff, Mitchell E. Horwitz, Thomas W. LeBlanc, et al. “Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.” Blood Cancer J 11, no. 5 (May 16, 2021): 92. https://doi.org/10.1038/s41408-021-00481-9.
    Full Text Open Access Copy Link to Item
  - Sung, Anthony D., Shekeab Jauhari, Sharareh Siamakpour-Reihani, Arati V. Rao, Janet Staats, Cliburn Chan, Everett Meyer, et al. “Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.” Am J Hematol 95, no. 6 (June 2020): 662–71. https://doi.org/10.1002/ajh.25781.
    Full Text Link to Item
  - Hudson, Kathryn E., David Rizzieri, Samantha M. Thomas, Thomas W. LeBlanc, Zachary Powell, Louis Diehl, Joseph O. Moore, Carlos DeCastro, and Anne W. Beaven. “Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study.” Br J Haematol 184, no. 4 (February 2019): 647–50. https://doi.org/10.1111/bjh.15138.
    Full Text Link to Item
  - Heyman, Benjamin, David Rizzieri, David J. Adams, Carlos De Castro, Louis Diehl, Zhiguo Li, Joseph Moore, and Anne Beaven. “Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.” Clin Lymphoma Myeloma Leuk 18, no. 10 (October 2018): 679–86. https://doi.org/10.1016/j.clml.2018.07.285.
    Full Text Link to Item
  - Troy, Jesse D., Carlos M. de Castro, Mary Ruth Pupa, Greg P. Samsa, Amy P. Abernethy, and Thomas W. LeBlanc. “Patient-Reported Distress in Myelodysplastic Syndromes and Its Association With Clinical Outcomes: A Retrospective Cohort Study.” J Natl Compr Canc Netw 16, no. 3 (March 2018): 267–73. https://doi.org/10.6004/jnccn.2017.7048.
    Full Text Link to Item
  - Tuchman, Sascha A., Joseph O. Moore, Carlos D. DeCastro, Zhiguo Li, Emily Sellars, Yubin Kang, Gwynn Long, and Cristina G. Gasparetto. “Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.” J Geriatr Oncol 8, no. 3 (May 2017): 165–69. https://doi.org/10.1016/j.jgo.2017.02.004.
    Full Text Link to Item
  - Greenberg, Peter L., Richard M. Stone, Aref Al-Kali, Stefan K. Barta, Rafael Bejar, John M. Bennett, Hetty Carraway, et al. “Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 15, no. 1 (January 2017): 60–87. https://doi.org/10.6004/jnccn.2017.0007.
    Full Text Link to Item
  - Griffin, Patrick T., Rami S. Komrokji, Carlos M. De Castro, David A. Rizzieri, Magda Melchert, Alan F. List, and Jeffrey E. Lancet. “A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.” Am J Hematol 90, no. 9 (September 2015): 796–99. https://doi.org/10.1002/ajh.24087.
    Full Text Link to Item
  - Greenberg, Peter L., Richard M. Stone, Rafael Bejar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, et al. “Myelodysplastic syndromes, version 2.2015.” J Natl Compr Canc Netw 13, no. 3 (March 2015): 261–72. https://doi.org/10.6004/jnccn.2015.0038.
    Full Text Link to Item
  - Brander, Danielle, David Rizzieri, Jon Gockerman, Louis Diehl, Thomas Charles Shea, Carlos Decastro, Joseph O. Moore, and Anne Beaven. “Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.” Leuk Lymphoma 54, no. 12 (December 2013): 2627–30. https://doi.org/10.3109/10428194.2013.784969.
    Full Text Link to Item
  - Greenberg, Peter L., Eyal Attar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H Joachim Deeg, et al. “Myelodysplastic syndromes: clinical practice guidelines in oncology.” J Natl Compr Canc Netw 11, no. 7 (July 2013): 838–74. https://doi.org/10.6004/jnccn.2013.0104.
    Full Text Link to Item
  - Held, Lauren A., David Rizzieri, Gwynn D. Long, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Mitchell E. Horwitz, Nelson J. Chao, and Cristina Gasparetto. “A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.” Cancer Invest 31, no. 3 (March 2013): 172–76. https://doi.org/10.3109/07357907.2012.756109.
    Full Text Link to Item
  - Hillmen, P., P. Muus, A. Röth, M. O. Elebute, A. M. Risitano, H. Schrezenmeier, J. Szer, et al. “Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.” British Journal of Haematology 162, no. 1 (2013): 62–73. https://doi.org/10.1111/bjh.12347.
    Full Text
  - Morris, Tod A., Carlos M. DeCastro, Louis F. Diehl, Jon P. Gockerman, Anand S. Lagoo, Zhiguo Li, Joseph O. Moore, David A. Rizzieri, and Arati V. Rao. “Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia.” Leuk Res 37, no. 1 (January 2013): 28–31. https://doi.org/10.1016/j.leukres.2012.09.016.
    Full Text Link to Item
  - Rao, A. V., D. A. Rizzieri, C. M. DeCastro, L. F. Diehl, A. S. Lagoo, J. O. Moore, and J. P. Gockerman. “Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML.” Journal of Geriatric Oncology 3, no. 3 (July 1, 2012): 220–27. https://doi.org/10.1016/j.jgo.2012.02.002.
    Full Text
  - Mohanty, Bibhu D., and Carlos M. De Castro. “Too many clots for comfort.” Am J Med 125, no. 3 (March 2012): 243–45. https://doi.org/10.1016/j.amjmed.2011.09.002.
    Full Text Link to Item
  - Lanasa, Mark C., Patricia H. Davis, Michael Datto, Zhiguo Li, Jon P. Gockerman, Joseph O. Moore, Carlos M. DeCastro, et al. “Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.” Leuk Lymphoma 53, no. 2 (February 2012): 218–24. https://doi.org/10.3109/10428194.2011.610012.
    Full Text Link to Item
  - Christensen, Dale J., Youwei Chen, Jessica Oddo, Karen M. Matta, Jessica Neil, Evan D. Davis, Alicia D. Volkheimer, et al. “SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.” Blood 118, no. 15 (October 13, 2011): 4150–58. https://doi.org/10.1182/blood-2011-04-351072.
    Full Text Link to Item
  - Greenberg, Peter L., Eyal Attar, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H Joachim Deeg, James M. Foran, et al. “NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.” J Natl Compr Canc Netw 9, no. 1 (January 2011): 30–56. https://doi.org/10.6004/jnccn.2011.0005.
    Full Text Link to Item
  - Advani, Anjali S., Mazyar Shadman, Francis Ali-Osman, Andrew Barker, Lisa Rybicki, Matt Kalaycio, Mikkael A. Sekeres, et al. “A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.” Clin Lymphoma Myeloma Leuk 10, no. 6 (December 2010): 473–76. https://doi.org/10.3816/CLML.2010.n.082.
    Full Text Link to Item
  - Dimopoulos, Meletios, Adrian Alegre, Edward A. Stadtmauer, Hartmut Goldschmidt, Jeffrey A. Zonder, Carlos M. de Castro, Zvenyslava Masliak, et al. “The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.” Cancer 116, no. 16 (August 15, 2010): 3807–14. https://doi.org/10.1002/cncr.25139.
    Full Text Link to Item
  - Crout, Christopher A., Liang-Piu Koh, Jon P. Gockerman, Joseph O. Moore, Carlos Decastro, Gwynn D. Long, Louis Diehl, et al. “Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.” Cancer Invest 28, no. 6 (July 2010): 654–60. https://doi.org/10.3109/07357901003631015.
    Full Text Link to Item
  - Gasparetto, Cristina, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Gwynn D. Long, Mitchell E. Horwitz, et al. “"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.” Biol Blood Marrow Transplant 16, no. 1 (January 2010): 70–77. https://doi.org/10.1016/j.bbmt.2009.08.017.
    Full Text Link to Item
  - Friedman, Daphne R., J Brice Weinberg, William T. Barry, Barbara K. Goodman, Alicia D. Volkheimer, Karen M. Bond, Youwei Chen, et al. “A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.” Clin Cancer Res 15, no. 22 (November 15, 2009): 6947–55. https://doi.org/10.1158/1078-0432.CCR-09-1132.
    Full Text Link to Item
  - Frytak, Jennifer R., Henry J. Henk, Carlos M. De Castro, Rachel Halpern, and Michael Nelson. “Estimation of economic costs associated with transfusion dependence in adults with MDS.” Curr Med Res Opin 25, no. 8 (August 2009): 1941–51. https://doi.org/10.1185/03007990903076699.
    Full Text Link to Item
  - Rizzieri, David A., Jenny A. O’Brien, Gloria Broadwater, Carlos M. Decastro, Prakash Dev, Louis Diehl, Anne Beaven, et al. “Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.” Cancer 115, no. 13 (July 1, 2009): 2922–29. https://doi.org/10.1002/cncr.24379.
    Full Text Link to Item
  - Castro, C. de, D. Adams, D. Rizzieri, J. Moore, J. Gockerman, L. Diehl, M. Horwitz, E. Edmonds, and J. Warzecho. “P134 A phase II pilot study of sorafenib in patients with myelodysplastic syndromes.” Leukemia Research 33, no. SUPPL. 1 (May 1, 2009). https://doi.org/10.1016/S0145-2126(09)70215-2.
    Full Text
  - Castro, C. de, D. Adams, D. Rizzieri, J. Moore, J. Gockerman, L. Diehl, M. Horwitz, E. Edmonds, and J. Warzecho. “P129 A pilot study of decitabine in combination with arsenic trioxide for patients with myelodysplastic syndromes.” Leukemia Research 33, no. SUPPL. 1 (May 1, 2009). https://doi.org/10.1016/S0145-2126(09)70210-3.
    Full Text
  - Grinblatt, David L., Daohai Yu, Vera Hars, James W. Vardiman, Bayard L. Powell, Sreenivasa Nattam, Lewis R. Silverman, et al. “Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).” Cancer 115, no. 1 (January 1, 2009): 84–93. https://doi.org/10.1002/cncr.23995.
    Full Text Link to Item
  - Weinberg, J. B., A. D. Volkheimer, M. Mihovilovic, N. Jiang, Y. Chen, K. Bond, J. O. Moore, et al. “Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia.” Leukemia 22, no. 12 (December 2008): 2184–92. https://doi.org/10.1038/leu.2008.241.
    Full Text Link to Item
  - Christensen, Dale J., Karen M. Bond, Alicia D. Volkheimer, Jessica Oddo, Youwei Chen, Jon P. Gockerrnan, Joseph O. Moore, et al. “Apolipoprotein E-Mimetic Therapeutic Peptides Mediate CLL Cell Cytotoxicity.” Blood 112, no. 11 (November 16, 2008): 140–140.
    Link to Item
  - Greenberg, Peter L., Eyal Attar, Minoo Battiwalla, John M. Bennett, Clara D. Bloomfield, Carlos M. DeCastro, H Joachim Deeg, et al. “Myelodysplastic syndromes.” J Natl Compr Canc Netw 6, no. 9 (October 2008): 902–26.
    Link to Item
  - Rao, Arati V., Islam R. Younis, Gregory J. Sand, Ivan Spasojevic, David J. Adams, Carlos M. Decastro, John P. Gockerman, et al. “Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.” Leuk Lymphoma 49, no. 8 (August 2008): 1523–29. https://doi.org/10.1080/10428190802210700.
    Full Text Link to Item
  - Brodsky, Robert A., Neal S. Young, Elisabetta Antonioli, Antonio M. Risitano, Hubert Schrezenmeier, Jörg Schubert, Anna Gaya, et al. “Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.” Blood 111, no. 4 (February 15, 2008): 1840–47. https://doi.org/10.1182/blood-2007-06-094136.
    Full Text Link to Item
  - Weinberg, J Brice, Alicia D. Volkheimer, Youwei Chen, Bethany E. Beasley, Ning Jiang, Mark C. Lanasa, Daphne Friedman, et al. “Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.” Am J Hematol 82, no. 12 (December 2007): 1063–70. https://doi.org/10.1002/ajh.20987.
    Full Text Link to Item
  - Fock, K. M., A. Wagner, M. A. Ahad, D. S. Ahmed, F. Ahmed, M. M. Ahmed, M. S. Ali, et al. “Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.” Journal of Gastroenterology and Hepatology (Australia) 22, no. 8 (August 1, 2007): 1190–98. https://doi.org/10.1111/j.1440-1746.2007.04955.x.
    Full Text
  - Frytak, J. R., H. J. Henk, C. M. de Castro, R. Halpern, and M. Nelson. “P132 Cost of transfusion dependency among managed care patients with myelodysplastic syndromes.” Leukemia Research 31 (May 2007): S111–12. https://doi.org/10.1016/s0145-2126(07)70202-3.
    Full Text
  - Rizzieri, David A., Liang Piu Koh, Gwynn D. Long, Cristina Gasparetto, Keith M. Sullivan, Mitchell Horwitz, John Chute, et al. “Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.” J Clin Oncol 25, no. 6 (February 20, 2007): 690–97. https://doi.org/10.1200/JCO.2006.07.0953.
    Full Text Link to Item
  - Anderson, Kenneth C., Melissa Alsina, William Bensinger, J Sybil Biermann, Asher Chanan-Khan, Raymond L. Comenzo, Carlos M. De Castro, et al. “Multiple myeloma. Clinical practice guidelines in oncology.” J Natl Compr Canc Netw 5, no. 2 (February 2007): 118–47. https://doi.org/10.6004/jnccn.2007.0014.
    Full Text Link to Item
  - Kantarjian, Hagop, Jean-Pierre J. Issa, Craig S. Rosenfeld, John M. Bennett, Maher Albitar, John DiPersio, Virginia Klimek, et al. “Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.” Cancer 106, no. 8 (April 15, 2006): 1794–1803. https://doi.org/10.1002/cncr.21792.
    Full Text Link to Item
  - Greenberg, Peter L., Maria R. Baer, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H Joachim Deeg, Marcel P. Devetten, et al. “Myelodysplastic syndromes clinical practice guidelines in oncology.” J Natl Compr Canc Netw 4, no. 1 (January 2006): 58–77.
    Link to Item
  - Wanko, Sam O., and Carlos de Castro. “Hairy cell leukemia: an elusive but treatable disease.” Oncologist 11, no. 7 (2006): 780–89. https://doi.org/10.1634/theoncologist.11-7-780.
    Full Text Link to Item
  - Talbot, Jeffrey, Valerie K. Ibom, David A. Rizzieri, Robert Barrier, Donna Niedzwieki, Carlos M. DeCastro, Joseph O. Moore, et al. “Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma.” Clin Lymphoma 5, no. 2 (September 2004): 116–22. https://doi.org/10.3816/clm.2004.n.018.
    Full Text Link to Item
  - Rizzieri, David A., Gamal Akabani, Michael R. Zalutsky, R Edward Coleman, Scott D. Metzler, James E. Bowsher, Bonnie Toaso, et al. “Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.” Blood 104, no. 3 (August 1, 2004): 642–48. https://doi.org/10.1182/blood-2003-12-4264.
    Full Text Link to Item
  - Rizzieri, David A., Gregory J. Sand, Dean McGaughey, Joseph O. Moore, Carlos DeCastro, Nelson J. Chao, James J. Vredenburgh, et al. “Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.” Cancer 100, no. 11 (June 1, 2004): 2408–14. https://doi.org/10.1002/cncr.20245.
    Full Text Link to Item
  - Nishimura, Jun-Ichi, Yuzuru Kanakura, Russell E. Ware, Tsutomu Shichishima, Hideki Nakakuma, Haruhiko Ninomiya, Carlos M. Decastro, et al. “Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan.” Medicine (Baltimore) 83, no. 3 (May 2004): 193–207. https://doi.org/10.1097/01.md.0000126763.68170.46.
    Full Text Link to Item
  - Ibom, Valerie K., Robert G. Prosnitz, Jerald Z. Gong, Joseph O. Moore, Carlos M. DeCastro, Leonard R. Prosnitz, David A. Rizzieri, and Jon P. Gockerman. “Rituximab in lymphocyte predominance Hodgkin's disease: a case series.” Clin Lymphoma 4, no. 2 (September 2003): 115–18. https://doi.org/10.3816/clm.2003.n.021.
    Full Text Link to Item
  - Talbot, Jeffrey, David A. Rizzieri, Carlos M. DeCastro, Joseph O. Moore, Patrick Buckley, Rhonda Laney, Diane Stevenson, Heather Brumbaugh, and Jon P. Gockerman. “High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case series.” Am J Hematol 73, no. 4 (August 2003): 295–96. https://doi.org/10.1002/ajh.10362.
    Full Text Link to Item
  - Heeney, Matthew M., Susan M. Ormsbee, M Anthony Moody, Thad A. Howard, Carlos M. DeCastro, and Russell E. Ware. “Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria.” Mol Genet Metab 78, no. 4 (April 2003): 291–94. https://doi.org/10.1016/s1096-7192(03)00047-7.
    Full Text Link to Item
  - Rizzieri, David A., Valerie K. Ibom, Joseph O. Moore, Carlos M. DeCastro, Gary L. Rosner, David J. Adams, Traci Foster, et al. “Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.” Clin Cancer Res 9, no. 2 (February 2003): 663–68.
    Link to Item
  - Castro, Carlos M. de. “Commentary: targeting myelodysplastic syndromes.” Leuk Res 26, no. 8 (August 2002): 703. https://doi.org/10.1016/s0145-2126(02)00024-3.
    Full Text Link to Item
  - Bass, Adam J., Jon P. Gockerman, Eve Hammett, Carlos M. DeCastro, David J. Adams, Gary L. Rosner, Nancy Payne, et al. “Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.” J Clin Oncol 20, no. 13 (July 1, 2002): 2995–3000. https://doi.org/10.1200/JCO.2002.08.166.
    Full Text Link to Item
  - Kornblith, Alice B., James E. Herndon, Lewis R. Silverman, Erin P. Demakos, Rosalie Odchimar-Reissig, James F. Holland, Bayard L. Powell, et al. “Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.” J Clin Oncol 20, no. 10 (May 15, 2002): 2441–52. https://doi.org/10.1200/JCO.2002.04.044.
    Full Text Link to Item
  - Silverman, Lewis R., Erin P. Demakos, Bercedis L. Peterson, Alice B. Kornblith, Jimmie C. Holland, Rosalie Odchimar-Reissig, Richard M. Stone, et al. “Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.” J Clin Oncol 20, no. 10 (May 15, 2002): 2429–40. https://doi.org/10.1200/JCO.2002.04.117.
    Full Text Link to Item
  - McCune, Steven L., Jon P. Gockerman, Joseph O. Moore, Carlos M. Decastro, Adam J. Bass, Nelson J. Chao, Gwynn D. Long, et al. “Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.” Leuk Lymphoma 43, no. 5 (May 2002): 1007–11. https://doi.org/10.1080/10428190290021597.
    Full Text Link to Item
  - Rizzieri, David A., Adam J. Bass, Gary L. Rosner, Jon P. Gockerman, Carlos M. DeCastro, William P. Petros, David J. Adams, et al. “Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.” J Clin Oncol 20, no. 3 (February 1, 2002): 674–79. https://doi.org/10.1200/JCO.2002.20.3.674.
    Full Text Link to Item
  - Ware, R. E., C. V. Pickens, C. M. DeCastro, and T. A. Howard. “Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes.” Exp Hematol 29, no. 12 (December 2001): 1403–9. https://doi.org/10.1016/s0301-472x(01)00746-9.
    Full Text Link to Item
  - Rizzieri, D. A., J. P. Gockerman, C. M. Decastro, S. Lilly, and T. Foster. “Phase i trial of continuously infused gemcitabine with cpt-11 for refractory hematologic malignancies.” Blood 96, no. 11 PART II (December 1, 2000).
  - Ware, R. E., C. V. Pickens, C. M. Decastro, and T. A. Howard. “Circulating pig-a mutant t lymphocytes in healthy adults and patients with bone marrow failure syndromes including pnh.” Blood 96, no. 11 PART I (December 1, 2000).
  - Castro, C. M. de, S. M. Rabe, S. D. Langdon, D. E. Fleenor, K. Slentz-Kesler, M. N. Ahmed, M. B. Qumsiyeh, and R. E. Kaufman. “Genomic structure and chromosomal localization of the novel ETS factor, PE-2 (ERF).” Genomics 42, no. 2 (June 1, 1997): 227–35. https://doi.org/10.1006/geno.1997.4730.
    Full Text Link to Item
  - Mann, K. P., C. M. DeCastro, J. Liu, J. O. Moore, S. H. Bigner, and S. T. Traweek. “Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes.” Am J Clin Pathol 107, no. 6 (June 1997): 653–60. https://doi.org/10.1093/ajcp/107.6.653.
    Full Text Link to Item
  - He, J., C. M. deCastro, G. R. Vandenbark, J. Busciglio, and D. Gabuzda. “Astrocyte apoptosis induced by HIV-1 transactivation of the c-kit protooncogene.” Proc Natl Acad Sci U S A 94, no. 8 (April 15, 1997): 3954–59. https://doi.org/10.1073/pnas.94.8.3954.
    Full Text Link to Item
  - Wuebbens, M. W., E. D. Roush, C. M. Decastro, and C. A. Fierke. “Cloning, sequencing, and recombinant expression of the porcine inhibitor of carbonic anhydrase: a novel member of the transferrin family.” Biochemistry 36, no. 14 (April 8, 1997): 4327–36. https://doi.org/10.1021/bi9627424.
    Full Text Link to Item
  - Fleenor, D. E., S. D. Langdon, C. M. deCastro, and R. E. Kaufman. “Comparison of human and Xenopus GATA-2 promoters.” Gene 179, no. 2 (November 14, 1996): 219–23. https://doi.org/10.1016/s0378-1119(96)00355-1.
    Full Text Link to Item
  - Vandenbark, G. R., Y. Chen, E. Friday, K. Pavlik, B. Anthony, C. deCastro, and R. E. Kaufman. “Complex regulation of human c-kit transcription by promoter repressors, activators, and specific myb elements.” Cell Growth Differ 7, no. 10 (October 1996): 1383–92.
    Link to Item
  - deCastro, C. M., S. M. Denning, S. Langdon, G. R. Vandenbark, J. Kurtzberg, R. Scearce, B. F. Haynes, and R. E. Kaufman. “The c-kit proto-oncogene receptor is expressed on a subset of human CD3-CD4-CD8- (triple-negative) thymocytes.” Exp Hematol 22, no. 10 (September 1994): 1025–33.
    Link to Item
  - Castro, C. M. de, B. Devlin, D. E. Fleenor, M. E. Lee, and R. E. Kaufman. “A novel beta-globin mutation, beta Durham-NC [beta 114 Leu-->Pro], produces a dominant thalassemia-like phenotype.” Blood 83, no. 4 (February 15, 1994): 1109–16.
    Link to Item
  - Bowen, D. T., R. A. Padua, A. K. Burnett, C. M. DeCastro, and R. E. Kaufman. “Two new polymorphisms but no mutations of the KIT gene in patients with myelodysplasia at positions corresponding to human FMS and murine W locus mutational hot spots.” Leukemia 7, no. 11 (January 1, 1993): 1883–85.
  - Vandenbark, G. R., C. M. deCastro, H. Taylor, S. Dew-Knight, and R. E. Kaufman. “Cloning and structural analysis of the human c-kit gene.” Oncogene 7, no. 7 (July 1992): 1259–66.
    Link to Item
- Conference Papers
  - De latour, Regis Peffault, Carlos M. De Castro, Jeffrey Szer, Kensuke Usuki, Peter Hillmen, Morag Griffin, Mohamed Hamdani, Temitayo Ajayi, Hisakazu Nishimori, and Ilene C. Weitz. “"Superiority of Pegcetacoplan Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria, Regardless of Prior Transfusion Requirement: Analysis at 16-weeks of PEGASUS Phase 3 Randomized Trial".” In British Journal of Haematology, 193:189–90, 2021.
    Link to Item
  - Griffin, Morag, Peter Hillmen, Jeffrey Szer, Ilene C. Weitz, Alexander Roeth, Britta Hoechsmann, Jens Panse, et al. “Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria.” In British Journal of Haematology, 193:63–65, 2021.
    Link to Item
  - Risitano, Antonio, Ilene C. Weitz, Carlos M. De Castro, Jean-Jacques Kiladjian, Morag Griffin, Hisakazu Nishimori, Mohamed Hamdani, Temitayo Ajayi, Scott B. Baver, and Regis Peffault de Latour. “Categorized hematologic response to pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria: post hoc analysis of data from a phase 3 randomized trial (PEGASUS).” In British Journal of Haematology, 193:24–25, 2021.
    Link to Item
  - Roeth, Alexander, Britta Hoechsmann, Morag Griffin, Carlos M. De Castro, Jeffrey Szer, Kensuke Usuki, Juliette Soret, et al. “Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab.” In British Journal of Haematology, 193:198–99, 2021.
    Link to Item
  - Sung, Anthony D., Carlos M. de Castro, Thomas W. LeBlanc, Gwynn D. Long, Donna B. Adams, Danielle M. Brander, Sandeep Dave, et al. “Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.
    Link to Item
  - Hillmen, Peter, Petra Muus, Alexander Röth, Modupe O. Elebute, Antonio M. Risitano, Hubert Schrezenmeier, Jeffrey Szer, et al. “Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.” In Br J Haematol, 162:62–73, 2013. https://doi.org/10.1111/bjh.12347.
    Full Text Link to Item
  - Beaven, Anne W., David A. Rizzieri, Zachary Powell, Zhiguo Li, Peggy Alton, Julie Warzecho, Louis F. Diehl, Joseph O. Moore, Carlos Manuel de Castro, and Jon P. Gockerman. “High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma.” In Blood, 118:1152–1152. AMER SOC HEMATOLOGY, 2011.
    Link to Item
  - Morris, Tod A., David A. Rizzieri, Carlos M. de Castro, Louis F. Diehl, Jon P. Gockerman, Anand S. Lagoo, Joseph O. Moore, and Arati V. Rao. “Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia.” In Blood, 118:1532–33. AMER SOC HEMATOLOGY, 2011.
    Link to Item
  - Lancet, Jeffrey E., Rami S. Komrokji, HuiYi Lin, Carlos M. de Castro, David A. Rizzieri, Magda Melchert, and Alan F. List. “Maintenance Therapy with Low-Dose Subcutaneous 5-Azacitidine in Older Patients with AML in 1st Remission.” In Blood, 114:425–26. AMER SOC HEMATOLOGY, 2009.
    Link to Item
  - Christensen, Dale J., Karen M. Bond, Alicia D. Volkheimer, Jessica Oddo, Youwei Chen, Jon P. Gockerman, Joseph O. Moore, et al. “The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.” In Blood, 114:802–802. American Society of Hematology, 2009. https://doi.org/10.1182/blood.v114.22.802.802.
    Full Text
  - Chi, Jen-Tsan Ashley, Carolyn Sangokoya, and Carlos M. De Castro. “MicroRNA expression in red blood cells from patients with PNH.” In Blood, 110:1073A-1073A. AMER SOC HEMATOLOGY, 2007.
    Link to Item
  - Weinberg, J Brice, Alicia D. Volkheimer, Mirta Mihovilovic, Ning Jiang, Youwei Chen, Joseph O. Moore, Jon P. Gockerman, et al. “Apolipoprotein E (APOE) Genotype as a Determinant of Survival in Women with Chronic Lymphocytic Leukemia.” In Blood, 110:3081–3081. American Society of Hematology, 2007. https://doi.org/10.1182/blood.v110.11.3081.3081.
    Full Text
  - Weinberg, J Brice, Ning Jiang, Alicia D. Volkheimer, Youwei Chen, Karen M. Bond, Joseph O. Moore, Jon P. Gockerman, et al. “Cytotoxicity of the Type 4 Phosphodiesterase Inhibitor CD160130 for Freshly Isolated Human CLL Cells In Vitro.” In Blood, 110:3129–3129. American Society of Hematology, 2007. https://doi.org/10.1182/blood.v110.11.3129.3129.
    Full Text
  - Silverman, L. R., D. R. McKenzie, B. L. Peterson, C. M. De Castro, J. Ellerton, K. N. Knapp, C. L. Beach, and R. A. Larson. “Response rates using international working group (IWG) criteria in patients with myelodysplastic syndromes (MDS) treated with azacitidine.” In Blood, 106:709A-709A. AMER SOC HEMATOLOGY, 2005.
    Link to Item
  - Gasparetto, Cristina, Mitchell E. Horwitz, Jon P. Gockerman, Carlos M. de Castro, Joseph O. Moore, Clay A. Smith, Patty Davis, et al. “Campath-1H May Have Activity in the Treatment of Multiple Myeloma.” In Blood, 104:4931–4931. American Society of Hematology, 2004. https://doi.org/10.1182/blood.v104.11.4931.4931.
    Full Text
  - Castro, C. M. de, H. Uronis, J. O. Moore, J. P. Gockerman, D. A. Rizzieri, and N. J. Chao. “Successful treatment of pure red cell aplasia (PRCA) with alemtuzumab (CAMPATH-1H).” In Blood, 102:19B-19B. AMER SOC HEMATOLOGY, 2003.
    Link to Item
Teaching & Mentoring
Recent Courses
- MEDICINE 402C: Medical Sub-Internship in Hematology-Oncology 2021
- MEDICINE 425C: Clinical Coagulation 2021

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Previous Appointments & Affiliations

Selected Grants

External Relationships

Selected Publications

Academic Articles

Conference Papers

Recent Courses